Cervical screening in Australia 1998–1999 is the third annual report based on key program activity, performance and outcome indicators to monitor the achievements of the National Cervical Screening Program. The report provides a comprehensive national picture of cervical screening in Australia for 1998–1999.

The report presents most recent information on participation in cervical screening, rate of early re-screening, low-grade and high-grade abnormalities detected, incidence of cervical cancer and mortality. Analysis of incidence and mortality data by location (rural, remote and metropolitan) as well as mortality by Indigenous status are also presented. Where possible, data are presented by State and Territory stratification.

This report will be relevant to anyone with an interest in women’s health or cervical screening, including health planners and administrators, various health practitioners, academic researchers and the general public.
Cervical Screening in Australia 1998-1999
The Australian Institute of Health and Welfare is Australia’s national health and welfare statistics and information agency. The Institute’s mission is to improve the health and wellbeing of Australians by informing community discussion and decision making through national leadership in developing and providing health and welfare statistics and information.
Cervical screening in Australia 1998-1999

Australian Institute of Health and Welfare
and the
Commonwealth Department of Health and Ageing
for the
National Cervical Screening Program

Australian Institute of Health and Welfare
Canberra
AIHW cat. no. CAN 11
# Contents

List of tables vi  
List of figures ix  
Acknowledgments x  
Summary xiii  
National Cervical Screening Program xv  

Cervical screening 1  
National cervical screening monitoring indicators 3  
Participation 7  
Indicator 1: Participation rate for cervical screening 9  

Early rescreening 13  
Indicator 2: Early rescreening 14  

Low-grade abnormalities 17  
Indicator 3: Low-grade abnormality detection 18  

High-grade abnormalities 19  
Indicator 4: High-grade abnormality detection 20  

Incidence 23  
Indicator 5: Incidence of micro-invasive cervical cancer 24  
Indicator 6: Incidence of squamous, adenocarcinoma, adeno-squamous and other cervical cancer 26  
Indicator 8: Incidence by location 30  

Mortality 33  
Indicator 7: Mortality 34  
Indicator 9: Mortality by location 37  
Indicator 10: Indigenous mortality 39  

Tables 41  

Appendixes 77  
Appendix A Cervical cancer: symptoms, detection and treatment 78  
Appendix B Data sources and limitations 79  
Appendix C Methods 81  
Appendix D Population data 83  
Appendix E NHMRC guidelines for the management of women with screen-detected abnormalities 86  

Glossary 89  
References 93  
Related publications 95
List of tables

Table 1: State and Territory registry commencement dates 2
Table 2: Structure of the Rural, Remote and Metropolitan Areas classification 5
Table 1a: Number of women participating in the National Cervical Screening Program by age, States and Territories, 1997-1998 42
Table 1b: Proportion of women participating in the National Cervical Screening Program by age, States and Territories, 1997-1998 43
Table 2a: Number of women participating in the National Cervical Screening Program by age, States and Territories, 1998-1999 44
Table 2b: Proportion of women participating in the National Cervical Screening Program by age, States and Territories, 1998-1999 45
Table 3: Number of women with repeat screenings in the 24 months following a negative Pap smear in February 1998 by States and Territories, and Australia, 1998-1999, and in the 24 months following a negative Pap smear in February 1997, Australia, 1997-1998 46
Table 4: Percentage of women with repeat screenings in the 24 months following a negative smear in February 1998 by States and Territories, and Australia, 1997-1998 and in the 24 months following a negative Pap smear in February 1997, Australia, 1998-1999 46
Table 5a: Number of low- and high-grade abnormalities on histology for women aged 20-69 years, by States and Territories, 1998 47
Table 5b: Number of low- and high-grade abnormalities on histology for women aged 20-69 years, by States and Territories, 1999 47
Table 6a: Rate of histologically confirmed high-grade abnormalities per 1,000 women screened, by States and Territories, 1998 48
Table 6b: Rate of histologically confirmed high-grade abnormalities per 1,000 women screened, by States and Territories, 1999 49
Table 7a: Number of histologically confirmed high-grade abnormalities by age, by States and Territories, 1998 50
Table 7b: Number of histologically confirmed high-grade abnormalities by age, by States and Territories, 1999 51
Table 8a: Number of women screened by age, by States and Territories, 1998 52
Table 8b: Number of women screened by age, by States and Territories, 1999 53
Table 9a: Age-standardised high-grade abnormality rate on histology per 1,000 women screened aged 20-69 years, States and Territories, 1998 54
Table 9b: Age-standardised high-grade abnormality rate on histology per 1,000 women screened aged 20-69 years, States and Territories, 1999 54
Table 10: New cases of micro-invasive cervical cancer by age, Australia, 1987-1998 55
Table 11: Age-specific and age-standardised rates of micro-invasive cervical cancer by age, Australia, 1987-1998
Table 12: New cases of cervical cancer by age, Australia, 1987-1998
Table 13: Age-specific and age-standardised incidence rates of cervical cancer by age, Australia, 1987-1998
Table 14a: Number of new cases of cervical cancer by age, by States and Territories, for the 4-year period 1994-1997
Table 14b: Age-specific rates of cervical cancer by States and Territories, for the 4-year period 1994-1997
Table 15a: Number of new cases of cervical cancer by age, by States and Territories, for the 4-year period 1995-1998
Table 15b: Age-specific rates of cervical cancer by States and Territories, for the 4-year period 1995-1998
Table 16a: Number of new cases of cervical cancer by histological type for women aged 20-69 years, Australia, 1987-1998
Table 16b: Age-standardised incidence rates for cervical cancer by histological type for women aged 20-69 years, Australia, 1987-1998
Table 17a: Number of new cases of cervical cancer by histological type for women, all ages, Australia, 1987-1998
Table 17b: Age-standardised incidence rates for cervical cancer by histological type for women, all ages, Australia, 1987-1998
Table 18: Number of new cases of cervical cancer by age and location, 1995-1997 and 1996-1998
Table 19: Age-specific and age-standardised incidence rates for cervical cancer by age and location, 1995-1997 and 1996-1998
Table 20: Number of deaths from cervical cancer by age, Australia, 1989-1999
Table 21: Age-specific and age-standardised mortality rates for cervical cancer by age, Australia, 1989-1999
Table 22: Number of deaths from cervical cancer by age, States and Territories, for the 4-year period 1992-1995
Table 23: Age-specific and age-standardised mortality rates for cervical cancer by age, by States and Territories, for the 4-year period 1992-1995
Table 24: Number of deaths from cervical cancer by age, States and Territories, for the 4-year period 1996-1999
Table 25: Age-specific and age-standardised mortality rates for cervical cancer by age, by States and Territories, for the 4-year period 1996-1999
Table 26: Number of deaths from cervical cancer by age and location, 1996-1998 and 1997-1999

Table B1: Cervical screening indicators data sources

Table D1: Australian Standard Population and World Standard Population

Table D2: Hysterectomy fractions for women aged 18-80+ years, Australia, 1995

Table D3: Estimated resident female populations, by States and Territories, June 1998

Table D4: Estimated resident female populations, by States and Territories, June 1999
List of figures

Figure 1: Participation rates in the National Cervical Screening Program by age group, Australia, 1997-1998 and 1998-1999 9

Figure 2: Participation (age-standardised) in the National Cervical Screening Program by women aged 20-69 years, by States and Territories, 1997-1998 and 1998-1999 10

Figure 3: Proportion of women rescreened by number of screens during the 24-month period following a negative smear in February 1997 and 1998, Australia 14

Figure 4: Proportion of women rescreened by number of screens during the 24-month period following a negative smear in February 1998, by States and Territories 15

Figure 5: Ratio of low- to high-grade abnormalities by women aged 20-69 years, by States and Territories, 1998 and 1999 18

Figure 6: High-grade abnormalities per 1,000 women by age group, Australia, 1998 and 1999 20

Figure 7: Age-standardised rate of high-grade abnormalities per 1,000 women screened aged 20-69 years, by States and Territories, 1998 and 1999 21

Figure 8: Age-standardised incidence rates of micro-invasive squamous cell cancer, women aged 20-69 years, Australia, 1987-1998 24

Figure 9: Age-specific incidence rates of micro-invasive squamous cell cancer, women aged 20-69 years, Australia, 1997 and 1998 25

Figure 10: Age-standardised incidence rates of cervical cancer, Australia, 1987-1998 26

Figure 11: Age-specific incidence rates of cervical cancer, Australia, 1997 and 1998 27

Figure 12: Age-standardised cervical cancer incidence rates by women aged 20-69 years, by States and Territories, 1994-1997 and 1995-1998 28

Figure 13: Age-standardised incidence rates of cervical cancer by histological type by women aged 20-69 years, Australia, 1987-1998 29

Figure 14: Age-standardised incidence rates of cervical cancer by location by women aged 20-69 years, Australia, 1995-1997 and 1996-1998 30

Figure 15: Age-standardised mortality rates from cervical cancer, Australia, 1989-1999 34

Figure 16: Age-specific cervical cancer mortality rates by age group, Australia, 1988-1990 and 1997-1999 35

Figure 17: Age-standardised cervical cancer mortality rates by women aged 20-69 years, by States and Territories, 1992-1995 and 1996-1999 36

Figure 18: Age-standardised cervical cancer mortality rates by women aged 20-69 years, by location, 1996-1998 and 1997-1999 37

Acknowledgments

This report is funded by the Commonwealth Department of Health and Ageing. The assistance of the Cancer Screening Section in the Department is gratefully acknowledged.

The authors of this report are Dr Indrani Pieris-Caldwell, Dr Chris Stevenson and Mr John Harding from the Australian Institute of Health and Welfare. The authors wish to extend their gratitude to those persons working in the National Cervical Screening Program and members of the National Screening Information Advisory Group who provided data and comments for this report. The authors also acknowledge the input of the members of the National Advisory Committee to the National Cervical Screening Program, and the Australasian Association of Cancer Registries. Thanks are also extended to the New South Wales Cancer Council, and State and Territory health departments for their assistance in the production of this report. The support received from the staff at Health Registers and Cancer Monitoring Unit, Australian Institute of Health and Welfare, during the production of this report is gratefully acknowledged.

National Cervical Screening Program

New South Wales
- Ms Jayne Ross
- Mr Hassan Mamoon
- Ms Sacha Macansh
- Ms Jennifer Mitchell

South Australia
- Ms Sue Gilchrist
- Ms Penny Iosifidis

Tasmania
- Ms Valerie Gardner

Victoria
- Mr Paul Chandler
- Dr Heather Mitchell
- Ms Vicky Higgins
- Ms Cathy Burrows
- Mr Rory Wilby
- Ms Helen Farrugia

Australian Capital Territory
- Ms Alice Jones
- Mr Peter Couvee

Queensland
- Ms Jennifer Muller
- Mr Stephen Heim

Northern Territory
- Ms Karen Finch
- Mr Chris Moon

Western Australia
- Ms Gloria Sutherland
- Ms Nerida Steel

Commonwealth
- Ms Andriana Koukari
- Ms Liz Pugh
- Ms Miranda Cumpston
- Ms Vicki Shaw
National Screening Information Advisory Group

Dr Paul Jelfs (Chair, to July 2000)  Australian Institute of Health and Welfare
Dr Chris Stevenson (Chair, August 2000)  Australian Institute of Health and Welfare
Mr John Harding (Chair, from Sept. 2000)  Australian Institute of Health and Welfare
Professor Bruce Armstrong  New South Wales Cancer Council
Ms Valerie Gardner  BreastScreen Program Manager representative
Dr Julienne Grace  Royal College of Pathologists of Australia
Ms Bethane Hart (to Feb 2001)  Consumers’ representative
Ms Carlene Butavicius (from Feb. 2001)  Consumers’ representative
Ms Andriana Koukari (to July 2001)  Department of Health and Ageing
Ms Sarah Major (from July 2001)  Department of Health and Ageing
Dr Heather Mitchell  Chair, National Advisory Committee to the National Cervical Screening Program
Ms Jennifer Muller  Cervical Screening Program Manager representative
Prof Sally Redman  Chair, National Advisory Committee to BreastScreen Australia
Assoc Prof David Roder  South Australian Health Department
Summary

• Between the two periods 1997-1998 and 1998-1999 cervical screening participation rates of the target population (women aged 20 to 69 years) increased from 63.9% to 64.8%.

• There was a small increase in the participation rate in most 5-year age groups within the target age group between the two periods 1997-1998 and 1998-1999. The largest increase - of 4.6% - was in the age group 60-64 years.

• Overall, 2,777,324 women were screened for cervical abnormalities in the 1998-1999 period. This is an increase of 55,674 women screened compared with the 2,721,650 women screened during 1997-1998 period.

• Compliance with the recommended screening interval (two years following a negative smear) is crucial in maintaining the effectiveness and the cost efficiency of the Program. Of a cohort of women screened in February 1998 who had a negative Pap smear result, 43.1% were rescreened in two years or less. This is in contrast to 46.7% women who were rescreened in two years or less following a negative Pap smear in 1997.

• Of the 1998 cohort of women who had a negative Pap smear result, 35% had one additional smear, 7% had two additional smears, and less than 2% had three or more additional smears in the two years following their initial Pap smear.

• A low-grade abnormality includes atypia, warty atypia, possible CIN, equivocal CIN, and CIN 1, while a high-grade abnormality is defined to include CIN 1/2, CIN 2 and CIN 3 or adenocarcinoma in situ. The ratio of histologically confirmed low-grade abnormalities to high-grade abnormalities was 1.4 for Australia in 1999, the same as for 1998. The 1998 ratio does not include data for the Australian Capital Territory.

• In 1999, the National Cervical Screening Program detected 11,642 women with high-grade abnormalities compared with 10,704 women with high-grade abnormalities detected in 1998. This number was much higher in the younger age groups: in the 20-29 age group the rate of high-grade abnormalities was over 17 per 1,000 women screened whereas it was less than 2 per 1,000 in women aged 55 years and over.

• The number of new cases of cervical cancer declined in Australia in recent years. There were 868 new cases in Australia in 1998 compared with 1,086 new cases detected in 1987. Cervical cancer is one of the few cancers where screening can detect pre-cancerous lesions. Treatment can prevent a large proportion of these pre-cancerous lesions progressing to cancer.

• Cervical cancer is the 18th most common cause of cancer mortality in women, accounting for 220 deaths in 1999. The age-standardised mortality rate from cervical cancer declined in the target age group from 4.7 per 100,000 women to 2.0 per 100,000 women between the years 1990 and 1999. During the same period the age-standardised mortality rate for all ages also declined from 5.0 per 100,000 women to 2.5 per 100,000 women.

• Women in the target age group from remote locations experienced a relatively high mortality rate from cervical cancer (4.7 per 100,000 women); this compared with 2.4 deaths per 100,000 women for metropolitan and rural locations. However, between the periods 1996-1998 and 1997-1999, the age-standardised cervical cancer mortality rate declined in all locations (metropolitan, rural and remote).

• Only Western Australia, South Australia and the Northern Territory have Indigenous mortality registration data of sufficient quality to be publishable. For these jurisdictions, in the period from 1997-1999 there were 13 deaths (an age-standardised mortality rate of 15.8 per 100,000
women) from cervical cancer among Indigenous women in the target age group. This is over seven times the corresponding rate in non-Indigenous women (2.2 per 100,000 women). It does indicate a decline in mortality compared with the 1996-1998 mortality rate for Indigenous women in the target age group, which was 19.0 per 100,000 women. However, these rates are based on relatively small numbers of cases and may be subject to large variability. Despite the relatively large size of the apparent decline in the rate, it is still within the range of variation that would be expected due to chance, that is, it is not statistically significant.
The National Cervical Screening Program continues to be a vibrant component of women’s health in Australia. Cervical screening has been available in Australia for more than 35 years. Many women have grown up with the Program and regard a regular Pap smear as an integral aspect of their personal health care. This year we are able to show that, among women aged 20-69 years, the mortality rate from cervical cancer had declined by over 55% between 1989 and 1999. This is a remarkable achievement for any cancer over such a short time period. This achievement stands as a testimony to the commitment of women, health providers and government to the Program.

The National Advisory Committee continues to meet twice per year, with many of its members also contributing to the Working Groups. A new Working Group, the Aboriginal and Torres Strait Islander Women’s Forum, was established during 2000. The incidence and mortality from cervical cancer among Aboriginal and Torres Strait Islander women continues to be unacceptably high. The Forum will allow for a more concentrated effort to reduce this burden to be made at the national level. The Chair of the Forum is Ms Patricia Kurnoth.

The other four Working Groups continue.

The Education, Communication and Recruitment Working Group is developing national resources for women and health practitioners about early rescreening. These resources will include information on underscreening. Although early rescreening is a problem in many countries, Australia is one of the first countries to tackle the issue formally. Thus our achievements in this area could have both national and international benefit. This Working Group is chaired by Ms Sue Gilchrist.

The New Technologies Working Group maintains a watching brief on research, both within Australia and internationally, into new approaches to preventing cervical cancer. Given the large policy implications of adopting new technologies, high-quality evidence will be needed before changes are made. Mr Robert Rome is the Chair.

The Policy and Cost-Effectiveness Working Group is now well advanced in reviewing the screening policy. Particular emphasis is being given to the age range and the recommended rescreening interval. A review of the National Health and Medical Research Council’s ‘Guidelines for the Management of Women with Screen Detected Abnormalities’ is planned to begin later this year. The Chair of the Working Group is Ms Jennifer Muller.

The Quality Assurance Working Group, chaired by Dr Annabelle Farnsworth, continues work on the Performance Standards for Laboratories Reporting Cervical Cytology. Compliance with the Standards has been mandatory for laboratory accreditation since 1 July 1999. Survey instruments have been completed for a study of the quality of reporting of cervical histopathology by Australian laboratories. This study will complement our understanding of pathology laboratory services for the cervical health of women.

This third annual report of key performance indicators for the National Cervical Screening Program is particularly welcomed. The Report’s usefulness to the Program and its accountability to the community, to health professionals and to Government make it a valued publication.